My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Cipla Ltd Research Report - 11th Nov 2016

Pharmaceutical | Published on Nov 11th 2016


Cipla posted numbers lower than expected for 2QFY2017. The company posted sales of Rs3,672cr vs. Rs3,737cr expected, registering a yoy growth of 8.7%, mainly aided by domestic formulations. Domestic formulation (Rs1,522cr) grew by 11.3% yoy, while exports (Rs2150cr) grew by 7.5% yoy. On the operating front, the EBITDA margin came in at 16.4% vs. 16.5% expected vs. 21.0% in 2QFY2016, mainly on back of base effect. Consequently, the Adj. PAT came in at Rs354cr vs. Rs498cr expected vs. Rs543cr in 2QFY2016, a yoy de-growth of 34.7%. We maintain our Reduce rating on the stock.

Download Full Report


CMP 564
Target Price 490
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others17.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo